Regeneron Pharma Q2 Earnings Top Estimates with Record Sales Growth
Regeneron Pharmaceuticals reported Q2 2026 earnings that surpassed estimates, with a 17% revenue increase driven by record sales of Dupixent, EYLEA HD, and Libtayo. The strong performance led to an 11% EPS gain.
Regeneron Pharmaceuticals (REGN) topped Wall Street estimates for the second quarter of 2026, posting total revenue of $4.3 billion, up 17% year over year, alongside an 11% gain in non-GAAP earnings per share. The beat extends a run of recent quarters in which the company's immunology and ophthalmology franchises have outpaced expectations.
That growth continues to be powered by Regeneron's three lead franchises. Dupixent, sold through Regeneron's collaboration with Sanofi, posted global net sales growth to a new all-time high, EYLEA HD's U.S. net sales rose sharply, and Libtayo's global sales also climbed to a record. That breadth matters because investors have spent recent quarters worried about biosimilar and competitive pressure eroding the older EYLEA franchise as EYLEA HD takes over.
The quarter's strength reinforces Regeneron's position as one of the more diversified large-cap biotechs, with growth coming from an allergy and inflammation blockbuster, a next-generation eye treatment, and an oncology asset rather than a single product line.
Investors will now watch whether Regeneron can sustain this pace as EYLEA HD continues its transition from the legacy EYLEA franchise and as Libtayo's oncology indications expand. Pipeline updates and any commentary on competitive dynamics in the anti-VEGF and IL-4/IL-13 markets could be the next catalysts the market weighs.
Related Stocks
Powered by SentiSense - Intelligent Market Analysis